Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
/in Dendritic Cells, International Publications, NSCLC /von 2021-12-24 / ESMO Open 2022 Feb;7(1):100334Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-02 / Cancers (Basel) 2021 Nov;13(21)Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2021-04-21 / Oncol Lett 2021 Jun;21(6):482A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer
/in Hyperthermia, International Publications, NSCLC /von 2020-03-17 / J Adv Res 2020 Jul;24:175-182Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
/in Dendritic Cells, International Publications, NSCLC /von 2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-86Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
/in Dendritic Cells, International Publications, NSCLC /von 2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
/in Dendritic Cells, NSCLC /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de